Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1

OBJECTIVES: This study retrospectively investigated in which cycle measurable residual disease (MRD) is associated with prognosis in patients in first complete remission (CR1) of intermediate-risk acute myeloid leukemia (AML). METHODS: The study enrolled 235 younger patients with intermediate-risk A...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Lijie, Li, Yilu, Wu, Jiaying, Peng, Jie, Han, Xiaolin, Zhao, Hongmian, He, Chen, Li, Yuanyuan, Wang, Weimin, Zhang, Mengmeng, Li, Yafei, Sun, Hui, Cao, Haixia, Sang, Li’na, Jiang, Zhongxing, Yu, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668963/
https://www.ncbi.nlm.nih.gov/pubmed/36031670
http://dx.doi.org/10.1007/s12185-022-03441-6

Ejemplares similares

Ejemplares similares